Institut Paoli-Calmettes
institutpaolicalmettes.frLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
169
Active
53
Phase 3
9
Total enrollment
257,306
Pipeline matrix
Showing 21 of 21 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| busulfan | — | — | — | — | — | 5 | |
| Venetoclax | — | — | — | — | — | 1 | |
| Azacitidine | — | — | — | — | — | 1 | |
| fludarabine and treosulfan | — | — | — | — | — | 1 | |
| Dasatinib | — | — | — | — | — | 1 | |
| prophylactic donor lymphocyte | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| neoadjuvant EC-paclitaxel chemotherapy | — | — | — | — | — | 1 | |
| M1774 | — | — | — | — | — | 1 | |
| Fulvestrant | — | — | — | — | — | 1 | |
| Niraparib Oral Product | — | — | — | — | — | 1 | |
| BX2 | — | — | — | — | — | 1 | |
| BX3 | — | — | — | — | — | 1 | |
| BX4-Suspended | — | — | — | — | — | 1 | |
| IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB | — | — | — | — | — | 1 | |
| mFOLFIRINOX | — | — | — | — | — | 1 | |
| analysis of BTN and BTNL status | — | — | — | — | — | 1 | |
| Pre-treatment biopsy | — | — | — | — | — | 1 | |
| Post treatment biopsy | — | — | — | — | — | 1 | |
| Pre treatment blood sampling | — | — | — | — | — | 1 | |
| Post treatment blood sampling | — | — | — | — | — | 1 |
Next readouts
- 2022-08-22
- 2023-11
- 2026-07-07
- 2026-07-08
- 2027-03
- 2027-04-01
- 2027-05
- 2027-06-30
- 2027-09
- 2028-11-01
Top conditions
- Breast Cancer14
- Acute Myeloid Leukemia11
- Myelodysplastic Syndromes6
- Leukemia5
- Prostate Cancer5
- Cancer4
- Acute Leukemia4
- Pancreatic Cancer3
Frequently asked questions about Institut Paoli-Calmettes
- How many clinical trials does Institut Paoli-Calmettes have on ClinicalTrials.gov?
- Institut Paoli-Calmettes is listed as the lead sponsor on 169 clinical trials in ClinicalTrials.gov, 53 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Institut Paoli-Calmettes's trials are in Phase 3?
- 9 of Institut Paoli-Calmettes's trials are in Phase 3, spread across 21 active drug programs.
- What therapeutic areas does Institut Paoli-Calmettes focus on?
- Institut Paoli-Calmettes's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Leukemia, Prostate Cancer.
- When are Institut Paoli-Calmettes's next clinical trial readouts?
- Institut Paoli-Calmettes has 10 upcoming primary-completion readouts tracked here; the soonest is “Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer”, expected around 2022-08-22.